Dianthus Therapeutics (NASDAQ: DNTH) reported Q2 EPS of ($0.09), $0.77 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $760 thousand versus the consensus estimate of $297.42 thousand.

For earnings history and earnings-related data on Dianthus Therapeutics (DNTH) click here.